» Articles » PMID: 34159407

A Pathological Indicator for Dysthyroid Optic Neuropathy: Tritan Color Vision Deficiency

Overview
Specialty Ophthalmology
Date 2021 Jun 23
PMID 34159407
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate the sensitivity of the color vision test by Arden in patients with dysthyroid optic neuropathy (DON) to improve diagnosis.

Methods: In this observational, retrospective study, we included the medical records of 92 eyes (48 patients) with diagnosis of DON between 2008 and 2019 in order to evaluate the full spectrum of findings from the color vision test by Arden, and to determine potential importance of this test. Thirty-five patients were female, and 13 patients were male. The mean age was 58.0 years (range: 34-79) at the time of the DON diagnosis.

Results: Forty-one eyes displayed relatively good BCVA with ≤ 0.2 LogMAR. We found a protan value exceeding the threshold of ≥ 8% in 57 eyes (30 patients) at the time of the diagnosis. The sensitivity of protan was 61.9% (95% CI 51.2-71.8%), while that of tritan was a striking 98.9% (95% CI 94.1-99.9%). We discovered one pathological sign, tritan deficiency (based on a threshold of ≥ 8%) consistently in all eyes but one at the time of the diagnosis, regardless of the visual field defects or any changes in best-corrected visual acuity (BCVA).

Conclusion: We found blue-yellow (tritan) deficiency, to be a sensitive and reliable indicator of dysthyroid optic neuropathy. We conclude that, in cases with suspected DON, a color vision test that can detect tritan deficiency is an essential tool for the adequate assessment, diagnosis, and treatment of DON.

Citing Articles

The prevalence of red-green color vision deficiency and its related factors in an elderly population above 60 years of age.

Hashemi H, Shahidi A, Hashemi A, Jamali A, Mortazavi A, Khabazkhoob M Int J Ophthalmol. 2023; 16(9):1535-1541.

PMID: 37724279 PMC: 10475627. DOI: 10.18240/ijo.2023.09.22.


[Thyroid Eye Disease-Compressive Optic Neuropathy].

Kuebler A, Halfter K, Klingenstein A, Neuhann L, Enders C, Priglinger S Ophthalmologie. 2023; 120(8):832-837.

PMID: 37147532 DOI: 10.1007/s00347-023-01865-x.


Dysthyroid Optic Neuropathy and Barrett's Index - Revisiting the Cutoffs [Letter].

Goel R, Shah S Clin Ophthalmol. 2022; 16:3751-3752.

PMID: 36407501 PMC: 9673778. DOI: 10.2147/OPTH.S396665.


Selective deficits of S-cone in thyroid-associated ophthalmopathy patients without clinical signs of dysthyroid optic neuropathy.

Jin H, Yu X, Cao S, Wang M, Hu X, Ye J Front Neurosci. 2022; 16:990425.

PMID: 36213732 PMC: 9532696. DOI: 10.3389/fnins.2022.990425.


Insights into Current Management Strategies for Dysthyroid Optic Neuropathy: A Review.

Tagami M, Honda S, Azumi A Clin Ophthalmol. 2022; 16:841-850.

PMID: 35330749 PMC: 8939905. DOI: 10.2147/OPTH.S284609.


References
1.
Bartley G . The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994; 92:477-588. PMC: 1298522. View

2.
Neigel J, Rootman J, BELKIN R, Nugent R, Drance S, Beattie C . Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology. 1988; 95(11):1515-21. DOI: 10.1016/s0161-6420(88)32978-7. View

3.
Krill A, Smith V, Pokorny J . Further studies supporting the identity of congenital tritanopia and hereditary dominant optic atrophy. Invest Ophthalmol. 1971; 10(6):457-65. View

4.
Schneck M . Color vision defect type and spatial vision in the optic neuritis treatment trial. Invest Ophthalmol Vis Sci. 1997; 38(11):2278-89. View